A pilot RCT links psilocybin's 25 mg dose to reduced egocentric bias in alcohol use disorder, exposing a blind spot in how ...

First-in-human trial targets the amygdala with focused ultrasound in MDD, raising hard questions about biomarker selection, ...

Jon Himoff, Chief Product Officer of Image Analysis Group (IAG), on why purpose-built imaging platforms outperform assembled ...

Symphony RCT shows 55% closure rate in diabetic foot ulcers at 12 weeks, outperforming standard care alone with faster ...

VenaSeal cyanoacrylate closure healed 88% of venous leg ulcers with 92-day median healing time in 24-month study of excluded ...

Tekton Research's St. Louis site exceeded its enrollment goal in an Alzheimer's trial despite joining mid-stream as a rescue site.

AnnJi advances AJ201 into Phase 3 trial for Kennedy's disease, targeting 200 ambulatory patients globally with a potential ...

DHHS 2026 Unified Agenda proposes five clinical research rule changes affecting Phase 1 INDs, single IRB requirements, and ...

Niia Signature Patch achieves 20-minute glucose signal recovery after insulin bolus, addressing a key challenge in all-in-one ...

Survodutide delivers 13.1% weight loss in Phase III trial for obesity and type 2 diabetes, with significant glycemic ...

Lundbeck presents baseline enrollment data from Phase III MASCOT trial of amlenetug for multiple system atrophy, with ...

Mineralys presents Lorundrostat Phase 3 results from the Launch-HTN trial at ASN Kidney Week 2026, testing efficacy in ...